Products
Online Inquiry
Olomoucine
Cat. No.:
0225LY-1270
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Olomoucine regulates the cell cycle and demonstrates anti-melanoma activity by acting as an ATP-competitive inhibitor of ERK1/p44 MAP kinase and various Cdk/Cyclin complexes.
Synonym:
101622-51-9; 2-(2-Hydroxyethylamino)-6-benzylamino-9-methylpurine; Olomucine; 4erk; 6-(Benzylamino)-2-(2-hydroxyethylamino)-9-methylpurine; Ethanol, 2-[[9-methyl-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-; 2-((6-(Benzylamino)-9-methyl-9H-purin-2-yl)amino)ethanol; 2-{[6-(benzylamino)-9-methyl-9h-purin-2-yl]amino}ethanol; 2-(2-Hydroxyethylamino)-6-(benzylamino)-9-methylpurine; 2-(Hydroxyethylamino)-6-benzylamino-9-methylpurine; 6-Benzylamino-2-(2-hydroxyethylamino)-9-methylpurine; OLO; 2-{[6-(benzylamino)-9-methyl-9H-purin-2-yl]amino}ethan-1-ol
CAS No.:
101622-51-9
Compound CID:
4592
Formula:
C15H18N6
Formula Weight:
298.34
Specification
Relative Density:
1.36 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Olomoucine can be used in cell cycle studies to examine the selective inhibition of several cyclin-dependent kinases.
Library Information
Target:
ERK; CDK
Receptor:
Cdc2/CyclinB; Cdc2/CyclinA; CDK2/CyclinE; CDK5/p35; ERK
Pathways:
MAPK; Cell cycle/Checkpoint
Plate Number:
AOCL-17
Plate Location:
c7
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
50 mg/mL; 167.59 mM
